comprehensive -WSS

comprehensive

author：explore 2025-09-27 09:54:58 - browse：953

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Boeing's 1st astronaut flight bumped into next year, more repairs needed

hotspot

WSS

NYC plans to house migrants on an island in the East River

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

PBM reform efforts get punted in Congress

Dario to buy mental health app maker Twill in cash and stock deal

6 phony surgeries that take placebo to the extreme

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

entertainment

comprehensive

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Drug repurposing or repositioning? The language matters

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

How to save PrEP access — and even expand it

'The Exorcist' director William Friedkin dead at 87

Medicare proposal to cover medical devices draws a mixed reaction

At least 12 people were injured in a blast at a port in northwest Turkey

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mississippi candidates for statewide offices square off in party primaries

hotspot

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

A new nitrogen execution bill also undermines medical licensing

The Harvard botanist who searched for psychedelics in the Amazon

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

focus

hotspot

entertainment